WEDNESDAY, APRIL 1, 2009
| 11:00-13:00 |
Satellite Symposium sponsored by Novo Nordisk |
Hall B |
| 13:30-15:30 |
Satellite Symposium sponsored by Novo Nordisk |
Hall B |
| 13:30-15:30 |
Satellite Symposium sponsored by Merck Serono |
Hall D |
| 16:00-18:00 |
Satellite Symposium sponsored by Novo Nordisk |
Hall B |
| 16:00-18:00 |
Satellite Symposium sponsored by Mars Inc. |
Hall C |
| 16:00-18:00 |
Satellite Symposium sponsored by Bayer Schering Pharma |
Hall D |
| 18:30 |
Opening Session
Greetings
Mayor of Nice
Dean of the Faculty of Medicine
Sir George Alberti, UK
Honoring of Prof. Scott Grundy, USA and Prof. Jesse Roth, USA
Keynote Lecture:
Insulin action in trouble in the Metabolic Syndrome
Emmanuel Van Obberghen, Nice, France
Followed by Get-Together Reception |
Hall A |
THURSDAY, APRIL 2, 2009
| 08:30-10:30 |
Opening Plenary Session:
The Metabolic Syndrome: macro and micro facets |
Hall A |
| |
|
|
| Chairpersons: |
Jesse Roth, USA
Scott Grundy, USA |
|
The Metabolic Syndrome - 2009
Sir George Alberti, UK
Cellular and molecular basis of diabetes and Metabolic Syndrome
C. Ronald Kahn, USA
What genetics has taught us about the Metabolic Syndrome
Andrew Hattersley, UK
Developmental plasticity and human disease
Peter D. Gluckman, New Zealand
| 10:30–11:00 |
Coffee Break, Poster and Exhibition Visit |
|
| 11:00–12:30 |
Parallel Session:
Prevention of diabetes at the population level |
Hall A |
| |
|
|
| Chairpersons: |
Eberhard Standl, Germany
Anne-Marie Felton, UK |
|
Predicting diabetes: the use of scores
Jaakko Tuomilehto, Finland
The Finish diabetes prevention experience: DEHKO/FIN-D2D
Timo Saaristo, Finland
The European prevention effort (IMAGE, DE-plan)
Peter Schwarz, Germany
The Japanese program
Takashi Kadowaki, Japan
| 11:00–12:30 |
Parallel Session:
Fat at the center of the Metabolic Syndrome |
Hall B |
| |
|
|
| Chairperson: |
C. Ronald Kahn, USA |
|
The adipocyte at the center of the Metabolic Syndrome
Bruce M. Spiegelman, USA
Adipokynes (title TBC)
Philipp E. Scherer, USA
Losing the right weight: body fat composition
Matthias Blüher, Germany
FFA physiology in the Metabolic Syndrome
André Carpentier, Canada
| 11:00–12:30 |
Parallel Session:
Gender-specific aspects of the Metabolic Syndrome |
Hall C |
| |
|
|
| Chairperson: |
Avraham Karasik, Israel |
|
Epidemiology and pathophysiology of IGT/IFG gender differences
Jonathan Shaw, Australia
PCOS and obesity: insulin resistance and reproduction
Andrea Dunaif, USA
Gluco-metabolic abnormalities during pregnancy
Alberto de Leiva, Spain
Testosterone and the Metabolic Syndrome in men
Bruno Lunenfeld, Israel
| 11:00–12:30 |
Parallel Session: Free Communications |
Hall D |
| 12:30–14:00 |
Lunch Break, Poster and Exhibition Visit |
|
| 14:00-15:30 |
Parallel Session:
Dysglycemia in the geriatric age-group |
Hall A |
Longevity and insulin resistance
Nir Barzilai, USA
Metabolic approaches to increase human life span: preventing the consequences of aging by nutrition
Eric Ravussin, USA
The role of sirtuins in metabolism and longevity
David A. Sinclair, USA
Aging and insulin secretion: do we ever stop prevention?
Jeffrey B. Halter, USA
| 14:00-15:30 |
Parallel Session:
The gut in obesity and diabetes |
Hall B |
Gut microbes, human metabolism and obesity
Jeremy K. Nicholson, UK
Appetite and obesity: a gastroenterologist’s perspective
John McLaughlin, UK
Apetite and obesity: the gut as an endocrine organ
Rachel Batterham, UK
Metabolic consequences of bariatric surgery to treat obesity
Antonio E. Pontiroli, Italy
| 14:00-15:30 |
Parallel Session:
Newly completed and ongoing diabetes
prevention trials data |
Hall C |
| |
|
|
| Chairperson: |
Paul Zimmet, Australia |
|
ACT now - Pioglitazone
Ralph A. DeFronzo, USA
NAVIGATOR – Nateglinide and Valsartan
Rury R. Holman, UK
ORIGIN – resting the pancreas with exogenous insulin
Hertzel Gerstein, Canada
The CANOE trial – Metformin and Rosiglitazone
Bernard Zinman, Canada
Discussion: Is there a future for drug therapies that prevent diabetes?
Are we intervening too late and what is the right time?
Ralph A. DeFronzo, Rury R. Holman, Hertzel Gerstein, Bernard Zinman
| 14:00-15:30 |
Parallel Session: Free Communications |
Hall D |
| 15:30–16:00 |
Coffee Break, Poster and Exhibition Visit |
|
| 16:00–18:00 |
Plenary Session:
Should we redefine measurements of blood glucose control and categories of dysglycemia? |
Hall A |
| |
|
|
| Chairperson: |
Bernard Zinman, Canada |
|
Changing the paradigm for measures of diabetes control?
David Nathan, USA
Beyond HbA1c in diabetes: the glucose tetrad for guiding therapy
Louis Monnier, France
What are the current definitions (IFG, IGT, diabetes) and what were they based on?
Ed Horton, USA
Is there a need for change?
Paul Zimmet, Australia
| 18:15-20:15 |
Satellite Symposium sponsored by Eli Lilly and Company |
Hall A |
| |
|
|
| 18:15-20:15 |
Satellite Symposium sponsored by Takeda |
Hall C |
FRIDAY, APRIL 3, 2009
| 08:30–10:30 |
Parallel Session:
Insulin resistance and the brain |
Hall A |
| |
|
|
| Chairperson: |
Michael Brainin, Austria |
|
Molecular biology of brain insulin resistance
Simon Lovestone, UK
Brain insulin resistance in man; effect on response to feeding
Stephanie Amiel, UK
CNS control of peripheral insulin resistance
C. Ronald Kahn, USA
Brain insulin resistance and dementia
Suzanne Craft, USA
| 08:30–10:30 |
Parallel Session:
New treatment targets |
Hall B |
| |
|
|
| Chairperson: |
Harold Lebovitz, USA |
|
Integrated neurohormonal therapy of obesity
Alain Baron, USA
G-protein-coupled receptors and islet function
Bo Ahrén, Sweden
Glucokinase activators
Joseph Grimsby, USA
Fibroblast growth factor 21 (FGF-21)
Alexei Kharitonenkov, USA
New treatment targets
David Moller, USA
| 08:30-10:30 |
Parallel Session:
Nutrition in obesity and the Metabolic Syndrome |
Hall C |
Nutrigenetics and nutrigenomics: nutritional modulation of people genetically at risk
Jose Ordovas, USA
How important is the glycemic index in obesity and the Metabolic Syndrome?
Andreas Pfeiffer, Germany
The role of vitamin D and calcium in type 2 diabetes
Anastassios G. Pittas, USA
Nutrition and endothelial dysfunction: acute and chronic effects
Antonio Ceriello, UK
| 08:30-10:30 |
Parallel Session: Free Communications |
Hall D |
| 10:30–11:00 |
Coffee Break, Poster and Exhibition Visit |
|
| 11:00-12:30 |
Parallel Session:
The role of exercise |
Hall A |
| |
|
|
| Chairperson: |
Sir George Alberti, UK |
|
Non-Exercise Activity Thermogenesis (NEAT)
James A. Levine, USA
The role of physical exercise in prevention of diabetes in people with IGT
David Nathan, USA
Exercise in the Finnish Prevention Study
Jaakko Tuomilehto, Finland
Effects of aerobic training, resistance training, or both on glycemic control in type 2
diabetes: a randomized trial
Ron J. Sigal, Canada
| 11:00–12:30 |
Parallel Session:
The ß-Cell in prediabetes |
Hall B |
| |
|
|
| Chairperson: |
Ralph A. DeFronzo, USA |
|
Regulation of ß-cell turnover
Philippe A. Halban, Switzerland
Sensing of nutrients and neural control
Randy Seeley, USA
β-cell survival mechanisms
Michael Walker, Israel
Lessons from drugs (PPAR, GLP-1, insulin)
Steven E. Kahn, USA
| 11:00–12:30 |
Parallel Session:
Hepatic steatosis |
Hall C |
Molecular and cellular pathogenesis of Non-Alcoholic Fatty Liver Disease
Jacob George, Australia
Non-Alcoholic Steato-hepatitis in children
Eve Roberts, Canada
Metabolic Syndrome, prediabetes, diabetes and NAFLD: future shock
Diabetologist: Ralph A. DeFronzo, USA
Hepatologist: Giovanni Tarantino, Italy
| 11:00–12:30 |
Parallel Session: Free Communications |
Hall D |
| 12:30–14:00 |
Lunch Break, Poster and Exhibition Visit |
|
| 14:00-15:30 |
Parallel Session:
Prediabetes/Metabolic Syndrome in the young |
Hall A |
The metabolic syndrome in children and adolescents
Gary Wong, Hong Kong
Childhood body mass index and risk of coronary heart disease in adulthood
Thorkild I. Sorensen, Denmark
Co-morbidities in obese children
Moshe Phillip, Israel
Insulin resistance, components of the metabolic syndrome, and biomarkers of
endothelial dysfunction in youth
Silva Arslanian, USA
| 14:00-15:30 |
Parallel Session:
The PPAR family: very much alive! |
Hall B |
Ligand, genetics and mechanism of action
Markku Laakso, Finland
The PPAR family of nuclear receptors, the Metabolic Syndrome, and CVD
Bart Staels, France
PPARs and diabetic complications – the FIELD trial
Marja-Riitta Taskinen, Finland
Regulation of lipid metabolism by PPAR gamma agonists
Henry Ginsberg, USA
| 14:00-15:30 |
Parallel Session:
GLP-1 in prediabetes and diabetes |
Hall C |
Rationale for GLP-1 treatment
Daniel Drucker, Canada
Incretin role in postprandial blood glucose regulation
Michael Nauck, Germany
Incretin-based treatment in prediabetes
Avraham Karasik, Israel
Novel GLP-1 related treatments
Jens J. Holst, Denmark
| 14:00-15:30 |
Parallel Session: Free Communications |
Hall D |
| 15:30–16:00 |
Coffee Break, Poster and Exhibition Visit |
|
| 16:00–18:00 |
Joint ICCR-PMS III Plenary Session:
Inflammation, abdominal obesity, and metabolic disease
Sponsored by an educational grant from the
International Chair on Cardiometabolic Risk |
Hall A |
| |
|
|
| Chairpersons: |
Jean Pierre Despres, Canada
Hannah Kanety, Israel
|
|
Inflammatory pathways and E-R stress in metabolic disease
Gokhan Hotamisligil, USA
Abdominal obesity, type 2 diabetes and inflammation
Peter Libby, USA
Anti-inflammatory properties of HDL
Philip Barter, Australia
Weight loss to reduce inflammation: review of the evidence
Luc Van Gaal, Belgium
| 18:15-20:15 |
Satellite Symposium sponsored by Solvay |
Hall D |
SATURDAY, APRIL 4, 2009
| 08:30-10:30 |
Plenary Session:
Dysglycemia and CVD: lessons from large cohort studies |
Hall A |
| |
|
|
| Chairperson: |
Markolf Hanefeld, Germany
|
|
Prediabetes and cardiovascular mortality
Paul Zimmet, Australia
Incidence and genetic risk factors for CV events: the EpiDREAM study
Hertzel Gerstein, Canada
Predicting diabetes and other outcomes: the Framingham Studies
Peter W. Wilson, USA
The epidemiologic and physiologic relevance of surrogate markers for CV events
Naveed Sattar, UK
Should triglyceride be targeted to reduce cardiovascular disease risk?
Helen M. Colhoun, Ireland
| 10:30–11:00 |
Coffee Break and Exhibition Visit |
|
| 11:00–13:00 |
Plenary Session:
New data on glucose/body weight lowering
interventions and CV outcomes |
Hall A |
| |
|
|
| Chairperson: |
Scott Grundy, USA
|
|
Do TZDs reduce atherosclerosis in diabetes? The IVUS studies
(APPROACH, PERISCOPE, VICTORY)
Robert Ratner, USA
Do TZDs reduce atherosclerosis in prediabetes? DREAM IMT studies
Hertzel Gerstein, Canada
Mode of treatment and CV outcomes in people with dysglycemia
Ongoing studies: (BARI 2D, ORIGIN, ACE)
Henry Ginsberg, USA
Completed studies: (VADT, ACCORD, ADVANCE)
Rury Holman, UK
Does weight lowering reduce CVD events?
(SCOUT, CRESCENDO, SOS, STRADIVARIUS)
Luc Van Gaal, Belgium
Round Table: Does glucose lowering reduce CV outcomes?
Chairperson: Rury Holman, UK
Speakers: Robert Ratner, Hertzel Gerstein, Henry Ginsberg, Luc Van Gaal